N-(2-hydroxy-5-methylbenzoyl)glycine | 1016695-31-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-hydroxy-5-methylbenzoyl)glycine
• 英文别名: 2-[(2-Hydroxy-5-methylbenzoyl)amino]acetic acid
• CAS: 1016695-31-0
• 化学式: C₁₀H₁₁NO₄
• 分子量: 209.202
• InChiKey: YCYYMCTXTWEGCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(2-羟基-5-甲基苯甲酰基)甘氨酸甲酯 在 水 、 sodium hydroxide 作用下， 生成 N-(2-hydroxy-5-methylbenzoyl)glycine
  参考文献：
  名称：

  Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases

  摘要：

  已知和潜在的阿司匹林代谢物被评估为氧感应缺氧诱导转录因子（HIF）羟化酶的抑制剂；一些代谢物被发现能在细胞中稳定HIF-α。

  DOI：

  10.1039/b814440k

文献信息

• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERY OF BREMELANOTIDE
  申请人：NOVEN PHARMACEUTICALS, INC.

  公开号：US20180185440A1

  公开（公告）日：2018-07-05

  Described are topical, transdermal and transmucosal pharmaceutical compositions comprising bremelanotide that include bremelanotide or a pharmaceutically acceptable salt thereof and a permeation enhancer, in any form suitable for topical, transdermal or transmucosal delivery, including transmucosal delivery through the gastrointestinal tract after oral administration. Also provided are methods of making and using the pharmaceutical compositions.
• Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases
  作者：Benoit M. Lienard、Ana Conejo-García、Ineke Stolze、Christoph Loenarz、Neil J. Oldham、Peter J. Ratcliffe、Christopher J. Schofield

  DOI：10.1039/b814440k

  日期：——

  Known and potential aspirinmetabolites were evaluated as inhibitors of oxygen-sensing hypoxia-inducible transcription factor (HIF) hydroxylases; some of the metabolites were found to stabilise HIF-α in cells.

  已知和潜在的阿司匹林代谢物被评估为氧感应缺氧诱导转录因子（HIF）羟化酶的抑制剂；一些代谢物被发现能在细胞中稳定HIF-α。